CBD Boosts the Effectiveness of Phenobarbital in Newborn Seizure Model, Study Finds

OG article by Anthony Martinelli

November 28, 2025

In a promising advance for neonatal epilepsy, cannabidiol (CBD) amplifies phenobarbital's (PB) seizure-suppressing effects at subtherapeutic doses, according to Frontiers in Pediatrics research from Brazil's Federal Universities of Alagoas and Minas Gerais. Using 10-day-old Wistar rats induced with pentylenetetrazole seizures, the team pretreated subjects with CBD (30–200 mg/kg), PB (10–30 mg/kg), or combinations, assessing latency, duration, and severity.

Solo CBD offered dose-dependent but modest protection, while low-dose PB (10 mg/kg) proved ineffective alone. Strikingly, pairing it with CBD elicited synergistic benefits: at 30 mg/kg CBD, seizure latency extended significantly; higher doses curtailed duration and intensity, suggesting CBD enhances PB's GABAergic modulation without added toxicity.

For newborns with drug-resistant seizures, where PB remains first-line but fails 30–40% of cases, this combo could reduce dosing needs, minimizing sedation risks. Authors stress further pharmacokinetic and safety trials for clinical translation, given CBD's established pediatric epilepsy role via Epidiolex.

As cannabinoid research bridges neurology gaps, these findings spotlight adjunctive potential, offering hope for vulnerable infants through non-intoxicating, mechanism-complementary therapies.